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Abstract
Purpose The IGF and mTOR-pathways are considered as potential targets for therapy in patients with adrenocortical
carcinoma (ACC). This study aims to describe the IGF pathway in ACC and to explore the response to the combined
treatment with the IGF1R/IR inhibitor linsitinib, and mTOR inhibitors (sirolimus and everolimus) in in vitro models of ACC.
Methods The protein expression level of IGF2, IGF1R and IGF2R was evaluated by immunohistochemistry in 17 human
ACCs and the mRNA expression level of IGF1, IGF2, IGF1R, IR isoforms A and B, IGF2R, IGF-Binding-Proteins
[IGFBP]-1, 2, 3 and 6 was evaluated by RT-qPCR in 12 samples. In H295R and HAC15 ACC cell lines the combined
effects of linsitinib and sirolimus or everolimus on cell survival were evaluated.
Results A high protein expression of IGF2, IGF1R and IGF2R was observed in 82, 65 and 100% of samples, respectively. A
high relative expression of IGF2 mRNA was found in the majority of samples. The mRNA levels of the IRA were higher
than that of IRB and IGF1R in the majority of samples (75%). Linsitinib inhibits cell growth in the H295R and HAC15 cell
lines and, combined with sirolimus or everolimus, linsitinib showed a signiﬁcant additive effect.
Conclusions In addition to IGF2 and IGF1R, ACC express IGF2R, IRA and several IGFBPs, suggesting that the interplay
between the different components of the IGF pathway in ACC could be more complex than previously considered. The
addition of mTOR inhibitors to linsitinib may have stronger antiproliferative effects than linsitinib alone.
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Introduction
Malignant tumors of the adrenal cortex, deﬁned as adre-
nocortical carcinoma (ACC), are rare but aggressive cancers
for which new treatment options are required [1–4].
Although most ACCs are sporadic, ACCs rarely develop in
the context of certain genetic syndromes such as the
Beckwith–Wiedemann syndrome (BWS), Li-Fraumeni and
familial colorectal polyposis. The study of these syndromes
has supported the potential role of some molecular path-
ways in ACC pathogenesis [5]. Particularly, the BWS is a
genetic syndrome associated with childhood ACC, other
childhood tumors and a somatic overgrowth syndrome in
which deregulation of imprinted genes on chromosomal
locus 11p15 leads to biallelic expression of IGF2 [5, 6].
Although the estimated prevalence of BWS in patients with
ACC is very low and restricted to the childhood [5, 7], IGF2
has been reported to be over-expressed in about 70–90% of
sporadic ACCs as compared to normal adrenals or benign
adrenocortical tumors [8–17]. Therefore, the insulin-like
growth factor (IGF) system is considered as a promising target
for new medical treatment options in ACC [11, 14, 18]. The
IGF system participates in the regulation of growth, lifespan
and metabolism and includes circulating ligands, exerting their
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effects as endocrine and/or paracrine factors [insulin, IGF1 and
IGF2 (IGFs)]; binding proteins (IGFBP1-6 that modulate
the bioavailability of IGFs) and multiple receptors [19].
Among the receptors, the IGF1 receptor (IGF1R) and the
insulin receptor isoforms A and B (IRA and IRB) are
tyrosine-kinase receptors. The mannose 6-phosphate/insu-
lin-like growth factor 2 receptor (IGF2R) is a scavenger
receptor involved in the internalization and degradation of
IGF2. In adult humans, insulin predominantly exerts
metabolic effects through the activation of IRB, whereas
IGFs, particularly IGF1, mainly exerts growth-stimulating
effects through the activation of IGF1R receptors. IRA is
predominantly expressed during fetal development when it
is an important mediator of pro-growth effects of insulin
and IGFs. IRA and its expression in malignant tumor tissue
has been suggested to be involved in cancer development
[19, 20]. Currently, the efﬁcacy of several IGF1R and
IGF1R/IR inhibitors is evaluated in clinical trials, alone or
in combination with other agents for the treatment of several
malignant disorders [21–23]. mTOR is a protein kinase of
the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR sig-
naling pathway and plays a pivotal role in cell growth,
metabolism and proliferation, by mediating the effects of
various growth factors, including the IGFs [24]. The mTOR
pathway is considered a target for antineoplastic therapy in
several malignancies and it has recently been proposed as a
target for ACC treatment [25–28].
This study aims at describing the IGF pathway in ACC
and to explore the in vitro response to the combined treat-
ment with a dual IGF1R/IR inhibitor (linsitinib) and the
mTOR inhibitor (sirolimus) in an in vitro model of ACC
using ACC cell lines.
Materials and methods
Subjects
Seventeen ACCs and 6 normal adrenal tissue samples (NA)
samples were used for this study. Fresh tissue was snap
frozen within 60 minutes after surgical removal. NA sam-
ples were collected for in vitro studies from adrenalectomy
(NA) due to renal cell carcinoma. This study was approved
by the Medical Ethics Committee of the Erasmus MC and
all patients gave written informed consent.
The following clinical parameters were recorded in all
patients: date of diagnosis, age, gender, ENSAT stage [29],
Weiss score (assessed by an expert pathologist in adrenal
disease [RRdK]) [30], mitotic count (as deﬁned by the
presence number of mitoses equal or higher than 5 in 50
high-power ﬁelds), hormonal status and type of hormonal
secretion (cortisol and/or androgens and/or estrogens and/or
mineralocorticoids) [31].
Total RNA isolation and quantitative RT-PCR
(RT-qPCR)
From snap frozen adrenal tissues (available for 12 ACCs
cases and 6 NA cases), total RNA was isolated using a
commercially available kit (High Pure RNA Tissue kit;
Roche, Almere, The Netherlands).
Total RNA from the human ACC cell line NCI-H295R
(H295R) was used as a positive control.
The cDNA synthesis from total RNA and quantitative
PCR were performed as previously described [25]. mRNA
expression of IGF1, IGF2, IGF1R, IRA, IRB, IGF2R,
IGFBP 1, 2, 3 and 6 and of the housekeeping gene
hypoxanthine phosphoribosyltransferase (HPRT) was eval-
uated by RT-qPCR in human ACC tissue samples,
depending on the availability of frozen tissues.
The primers and probes were purchased from Sigma-
Aldrich (Zwijndrecht, The Netherlands) and are reported in
the Supplemental table 1. Samples were normalized to the
expression of HPRT. PCR efﬁciencies (E) were calculated
for the primer-probe combinations used [32]. The relative
expression of genes was calculated using the comparative
threshold method, 2–ΔCt [33], after efﬁciency correction [34]
of target and reference gene transcripts (HPRT).
Immunohistochemistry (IHC)
The expression of IGF2, IGF1R and IGF2R in adrenal samples
was evaluated. Parafﬁn embedded tissue specimens were cut in
5 μm sections, deparafﬁnized and dehydrated. Antigen-retrieval
was performed by microwave treatment in Tris–EDTA Buffer
(pH 9.0). The slides were cooled for 1 h at+ 4 °C and incu-
bated for 1 h at room temperature (RT) with the primary
monoclonal antibodies and incubated overnight at+ 4 °C with
the primary polyclonal antibodies. The primary monoclonal
antibodie to detect IGF1R was purchased from Novus Biolo-
gicals (NB110-87052; dilution: 1:500) and the primary poly-
clonal antibodies to detect IGF2 and IGF2R were purchased
from R&D Systems (AF-292-NA; dilution: 1:500) and Santa
Cruz Biotech (SC-25462; dilution: 1:50) respectively. The
slides were washed and incubated for 30min at RT with sec-
ondary antibodies (Poly-AP-Goat anti-Mouse/Rabbit IgG
PowerVision+ ; ImmunoVision Technologies) at the con-
centration provided by the manufacturer. After washing,
staining was visualized by a 30min incubation in new fuchsin
solution. Only IGF1R staining was performed and visualized
with a Dako Detection System, following a different protocol
previously described [25]. All slides were counterstained with
hematoxylin and coverslipped. Positive controls included cases
of adrenocortical cancer and normal human pancreas with
previously proven positivity at IHC for the protein evaluated.
Negative controls included omission of the primary antibody
and the incubation with secondary antibodies.
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The staining was evaluated independently by two
investigators and any discrepancy was resolved by a con-
sensus review. The results were interpreted in a semi-
quantitative manner by using an intensity-proportion
scoring system previously described [35]. The score was
calculated by the sum of the intensity score and the pro-
portion of the stained cells; this provided a score between 0
and 6. The proportion score was as follows: 0= no posi-
tivity (or less than 10%);+ 1= less than 1/3 tumor cell
positivity;+ 2= 1/3 to 2/3 tumor cell positivity; and+ 3=
more than 2/3 tumor cell positivity. The intensity score was
as follows:+ 1=weak staining;+ 2= intermediate stain-
ing;+ 3= strong staining. The score 0 was regarded as
negative; 2–3 as low; 4–5 as intermediate and 6 as high.
Finally adrenocortical tumors were dichotomously grouped
as having intermediate to high expression of the evaluated
protein and phospho-proteins (IHC score equal-higher than
4) or not (IHC score lower than 4).
Drugs and reagents
The dual IGF1R/IR inhibitor linsitinib and the mTOR
inhibitors sirolimus and everolimus were purchased from
LC Laboratories (Inc. Woburn, MA, USA) and prepared as
a 10−3M stock solution in dimethylsulfoxide (DMSO).
Compounds were stored at −20 °C and further diluted in
40% DMSO before the use. Final DMSO concentration,
also added as vehicle to controls, was 0.4%.
Cell lines and culture conditions
The human ACC cell lines H295R and HAC15 were
obtained from the American Type Culture Collection
(Manassas, VA) and from Dr. W. Rainey (as gift), respec-
tively. Short Tandem Repeat (STR) proﬁling using a
Powerplex Kit (Promega) of H295R gave results consistent
with those described in the ATCC database, thus conﬁrming
the H295R cell line identity. STR proﬁling of
HAC15 showed that HAC15 has a genetic proﬁle identical
to H295R, which is consistent with a previous report by
Rainey et al. that HAC15 is a clone of H295R [36]. The
cells were cultured as previously described in detail [25]
and utilized up to the 15th passage.
Measurement of total DNA content assay
Measurement of total DNA content per well was used to
determine the effects of the compounds on cell proliferation.
Cells were plated in 1 ml of medium in 24-well plates at the
density required to obtain a 65–70% cell conﬂuence in
the control groups at the end of the experiment. The
experiments were performed using medium containing high
(5% FCS) or low serum (1% FCS). Twenty-four hours later
compounds were added to wells in quadruplicate, medium
was refreshed at day 3 and fresh compounds were added
again. After 3 or 6 days of treatment with the selected
compounds, cells were harvested for DNA measurement, as
a measure of cell number. All controls were vehicle treated.
Measurement of total DNA content was previously descri-
bed in detail [37].
Apoptosis assay
Apoptosis has been studied using two methods: “DNA
fragmentation assay” and “MuseTM Annexin V & Dead Cell
Kit”.
DNA fragmentation assay
The cells were plated in 24-well plates and treated as above
described for the cell proliferation assay. After 24 h com-
pounds or vehicle were added and after 3 days of incuba-
tion, DNA fragmentation was determined using a
commercially available ELISA kit (Roche Diagnostic
GmbH, Penzberg, Germany). The standard protocol sup-
plied by the manufacturer was used. The same plates were
also analyzed for the measurement of total DNA content.
The amount of DNA-fragmentation (apoptosis) was cor-
rected for the total DNA content in each well.
MuseTM Annexin V & Dead Cell Kit (Millipore, Germany)
Cells were plated in 12-well plates at the density necessary
to obtain a 65–70% cell conﬂuence in the control groups at
the end of the experiment. Twenty-four hours later, sir-
olimus was added to wells in duplicate. Control groups
were vehicle-treated. After seventy-two hours of treatment,
cells were harvested by gentle trypsinization and processed
for staining according to the protocol provided by the
supplier of the assay. The experiments were repeated twice.
Cell cycle assay
The effects of compounds on cell cycle progression were
evaluated using the “MuseTM Cell Cycle Assay” (Millipore,
Germany). Cells were plated in 12-well plates at the density
necessary to obtain a 65–70% cell conﬂuence in the control
groups at the end of the experiment. Twenty-four hours later
sirolimus was added to wells in duplicate. Control groups
were vehicle-treated. After seventy-two hours of treatment,
cells were harvested by gentle trypsinization and processed
for ﬁxation and staining according to the protocol provided
by the supplier of the assay. The experiments were repeated
twice.
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Statistical analysis
All the experiments were carried out at least three times,
with the exception of the apoptosis assays and cell cycle
assay that were performed twice. The repeated experiments
gave comparable results. For the statistical analysis, statis-
tical software SPSS (SPSS 15.0; SPSS Inc., Chicago, IL)
and GraphPad Prism 5.0 (GraphPhad Software, San Diego,
CA) were used. The Spearman’s rank coefﬁcient (rho) was
used to test correlation.
We used non-parametric tests to evaluate the differences
among groups (Mann–Whitney and Kruskall–Wallis). The
comparative statistical evaluations among treatment groups
were performed by ANOVA, followed by a multiple com-
parison test (Newman–Keuls).
Results
Study population
This study included samples from seventeen patients with
ACC (main clinical characteristics reported in Table 1).
Only two of the included ACC patients were children in
which the presence of a genetic cause was not known (case
6 and 8; 9.5 and 4.2 years old respectively).
To describe the IGF pathway, the protein expression
levels of IGF2, IGF1R and IGF2R were evaluated by IHC
in the ACC samples. In twelve of these samples, the mRNA
expression levels of IGF1, IGF2, IGF1R, IRA, IRB, IGF2R,
IGFBP 1, 2, 3 and 6 were evaluated by RT-qPCR.
mRNA expression of the components of the IGF
pathway in human ACC and NA samples
The mRNA expression of several components of the IGF
pathway was evaluated by RT-qPCR in 12 ACC samples
and in 6 NA samples. As shown in Fig. 1, the expression
levels of most of these IGF pathway components are quite
variable in the different samples evaluated, although a high
relative expression of IGF2 was found in the majority of
samples observed (mean 66,8 ± 106,4; median levels 24.82;
range 0.01–289.68). As compared with other receptors
evaluated, the receptor expressed at highest levels within
tumors was IRA in 7 of 12 samples (58.3%), IGF2R in 3
(25%), IGF1R in one (8.3%) and IRB in the remaining one
(8.3%). Considering only the tyrosine-kinase receptors, IRA
was the receptor expressed at highest levels in the majority
Table 1 IGF2, IGF1R and IGF2R protein expression in 17 adrenocortical cancer samples
Patient
number
Sex Weiss Hormonal
secretion
IGF2 protein expression IGF1R protein expression IGF2R protein expression
Score Considerable
expression
Score Considerable
expression
Score Considerable
expression
1 F 3 C 4 Yes 5 Yes 4 Yes
2 F 5 C and A 6 Yes 4 Yes 5 Yes
3 F 9 A 6 Yes 3 No 4 Yes
4 M 6 C and A 3 No 6 Yes 5 Yes
5 F 6 A 5 Yes 5 Yes 5 Yes
6 F 7 C and A 6 Yes 6 Yes 5 Yes
7 M 8 none 4 Yes 5 Yes 6 Yes
8 F 4 A 6 Yes 3 No 5 Yes
9 F 7 none 4 Yes 3 No 5 Yes
10 F 3 none 3 No 4 yes 5 Yes
11 F 7 C and A 6 Yes 4 Yes 5 Yes
12 F 5 A 5 Yes 6 Yes 6 Yes
13 F 7 none 4 Yes 3 No 4 Yes
14 F 8 none 6 Yes 3 No 5 Yes
15 M 4 A 6 Yes 4 Yes 6 Yes
16 F 6 none 6 Yes 2 No 5 Yes
17 M 6 C 3 No 5 Yes 6 Yes
Median 6;
Range 3–9
Median 5;
Range 3–6
Frequency 14/17
(82%)
Median 4;
Range 2–6
Frequency 11/17
(65%)
Median 5;
Range 4–5
Frequency 17/17
(100%)
F female, M male, C cortisol, A androgens
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of samples (83%). Mean levels of IRA were signiﬁcantly
higher than mean levels of IGF1R (0.25 ± 0.26 vs. 0.07 ±
0.09; p < 0.05). In all the evaluated samples, excepted for
three cases, IRA/IRB ratio was higher than 1 (2.19 ± 1.59).
As compared with other IGFBPs evaluated, the IGFBP
expressed at highest levels within tumors was IGFBP2 in 7
of 12 samples (58.3%); IGFBP3 in 4 (33.3%) and IGFBP6
in only one case (8.3%). Mean levels of IGFBP2 were
signiﬁcantly higher than the mean level of IGFBP1 and
IGFBP6 (1.16 ± 1.9 versus 0.04 ± 0.1; p < 0.01 and vs.
0.18 ± 0.07; p < 0.05, respectively). A negative correlation
was found between IGF2 and IGFBP6 (rho: −0.8; p <
0.003), whereas a positive correlation was found between
IGF1R and IGF2R (rho: 0.7; p < 0.009); IGF1R and IRB
(rho: 0.8; p < 0.003); IGF1R and IGFBP1 (rho: 0.8; p <
0.001) and IRA and IGFBP2 (rho: 0.8; p < 0.003). No
relationship was observed between the mRNA levels of the
IGF components and any clinical parameter evaluated
including hormone production, Weiss score, mitotic index
and TNM.
Fig. 1 mRNA expression levels of the main components of the IGFs and mTOR pathways (expressed as relative mRNA expression as normalized
to the housekeeping gene HPRT) in a series of 17 human ACC samples a and in a series of 6 normal adrenals b
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Mean levels of IGF1 and IGFBP6 were signiﬁcantly
lower in ACCs as compared with NAs (0.3 ± 0.4 versus
0.5 ± 0.3; p < 0.05 and 0.2 ± 0.2 vs. 2.0 ± 1.6, p < 0.01,
respectively). Mean levels of IGF2 were considerably
higher in ACCs as compared with NAs (66.8 ± 103.6 vs.
1.9 ± 2.3; p < 0.05), but this difference did not reach sta-
tistical signiﬁcance, probably as a consequence of the small
sample size and the high variation of IGF2 levels within the
tumor samples. Comparing the expression of the evaluated
components of the IGF pathway in the 12 ACCs evaluated
to the median value of each component in the NA, we
observed an over expression of: IRA in 7 cases (58%); IRB
in 4 (33,3%); IGF1 in 2 (17%); IGF2 in 9 (75%); IGF1R in
5 (41.6%); IGF2R in 5 (41.6%); IGFBP1 in 10 (83.3%);
IGFBP2 in 3 (25%); IGFBP3 in 9 (75%) and IGFBP6 in
none. In addition, 9 ACC samples showed an IRA-IRB ratio
higher than the median value observed in normal adrenals.
Protein expression of the components of the IGF
pathway in human ACC samples
The protein expression of IGF2, IGF1R and IGF2R was
evaluated by IHC in 17 human ACCs. Table 1 sum-
marizes the results of the IHC and the main clinical fea-
tures of the evaluated patients. An intermediate to high
staining for IGF2 (82%; median score 5; range 3–6) and
IGF1R (65%; median score 4; range 2–6) was observed in
most tumor tissues and for IGF2R (median score 5; range
4–6) in all ACCs. No correlations were observed between
the expression of the different proteins that were eval-
uated and between these proteins and the main clinical-
pathological characteristics of the corresponding patients.
No correlations were observed between the protein and
mRNA expression of IGF2, IGF1R and IGF2R although a
trend to positive correlation was found between IGF2
protein and mRNA expression. Figure 2 shows an
exemplary case of immunostaining in ACC. No particular
expression has been observed in the two childhood ACC
included in this series.
Effects of dual IGF1R/IR inhibitor in human
adrenocortical cell lines
In both H295R and HAC15 cell lines linsitinib inhibited cell
proliferation in a dose- and time-dependent manner (Fig. 3a,
d). Linsitinib was slightly, but signiﬁcantly, more potent in
inhibiting cell proliferation in HAC15 compared to H295R.
After 6 days of treatment in full medium the IC50 of linsi-
tinib in H295R was 1.5 × 10−7 M and in HAC15 2.9 × 10−8
M (p < 0.01). The maximal inhibition observed in H295R
and HAC15 was 90 and 95%, respectively (not statistically
signiﬁcant; p= 0.3). In both the H295R and HAC15 cells
the potency of linsitinib and the maximal inhibition
observed were similar in cell cultured in medium with high
serum compared with cells cultured in medium with low
serum (Fig. 3b, e). At the condition tested, linsitinib induced
DNA-fragmentation in a dose-dependent manner in both
H295R and HAC15 (Fig. 3c, f).
Fig. 2 Immunohistochemical
detection of IGF2 a, IGF1R b
and IGF2R c in a case of human
adrenocortical carcinoma. d
shows the absence of staining in
the negative control.
Magniﬁcation, ×200
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Effects of the dual IGF1R/IR inhibitor linsitinib in
combination with mTOR inhibitors on human ACC
cells
Sirolumus and everolimus inhibited cell proliferation in
H295R and HAC15 cells in a dose-dependent manner in
both experimental conditions tested (high versus low serum
concentration medium) data not shown. Sirolimus was
slightly, but not signiﬁcantly, more potent than everolimus.
The potency of both compounds was similar in medium
containing either high or low serum concentration. Selected
doses of sirolimus or everolimus combined with linsitinib
5 × 10−8 M had statistically signiﬁcant additive effect on
cell proliferation (Fig. 4). Particularly both concentrations
used of sirolimus and everolimus showed additive effect
with linsitinib in inhibiting H295R and HAC cell pro-
liferation when tested in medium containing low serum
concentration (Fig. 4b, d, f, h). Only the highest con-
centrations used of mTOR inhibitors (10−6 M) showed
some additive effect with linsitinib in inhibiting H295R and
HAC cell proliferation when tested in medium containing
high serum concentration (Fig. 4a, c, e, g).
At the condition tested, only the highest concentrations
used of sirolimus (10−6 M) showed signiﬁcant additive
effect with linsitinib in increasing annexin V, used as
measure of apoptosis, in H295R (Fig. 5a). Everolimus did
not show a statistically signiﬁcant additive effect in
increasing annexin V in H295R (Fig. 5b).
Linsitinib (10−7 M) alone or in combination with sir-
olimus 10−6M or 5 × 10−9 M signiﬁcantly increased the
proportion of cells in G0/G1 phase of the cell cycle (p <
0.05, p < 0.05 and p < 0.01 respectively). Linsitinib in
combination with sirolimus 10−6 M or 5 × 10−9 M sig-
niﬁcantly reduced the proportion of G2/M (p < 0.05) (Fig.
5c). Additionally the combined treatment with linsitinib and
sirolimus showed a trend to have additive effects in indu-
cing G1-cell cycle block. Statistically signiﬁcant additive
effects in increasing the proportion of cells in G0/G1 phase
(p < 0.05) and reducing the proportion of cells in G2/M
phase (p < 0.05) were observed when combining linsitinib
Fig. 3 Dose and time-dependent effect of linsitinib (OSI-906) treat-
ment on H295R a, b and HAC15 d, e cell proliferation, expressed as
DNA content/well after 3 days and 6 days a, d and after 6 days in
medium with high or low serum b, e. Dose-dependent effects of 3-day
treatment with linsitinib on apoptosis of H295R c and HAC15 f cells,
expressed as DNA fragmentation (normalized to the DNA content of
each well). Data are expressed as the percentage of control and
represent the mean ± SEM. Control is set as 100%. ***p < 0.001
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10−7 M and sirolimus 5 × 10−9 M as compared with sir-
olimus alone (Fig. 5c).
Linsitinib (10−7 M) alone or in combination with ever-
olimus 10−6M or 5 × 10−9 M signiﬁcantly increased the
proportion of cells in G0/G1 phase of the cell cycle (p <
0.01). Linsitinib alone or in combination with everolimus
10−6 M or 5 × 10−9 M signiﬁcantly reduced the proportion
of cells in G2/M phase (p < 0.01) (Fig. 5d). Additionally, the
combined treatment with linsitinib and everolimus showed
signiﬁcant additive effects in inducing G1-cell cycle block.
Particularly, when combining linsitinib 10−7 M and ever-
olimus 10−6 M or 5 × 10−9 M, statistically signiﬁcant addi-
tive effects in increasing the proportion of cells in G0/G1
phase (p < 0.05 and p < 0.01, respectively) and in reducing
the proportion of G2/M (p < 0.05) as compared with ever-
olimus alone were observed (Fig. 5d).
Discussion
The results of this study show that the majority of ACC
express IGF2, IGF1R and IGF2R mRNA and protein and
demonstrate IRA mRNA expression in these tumors, sug-
gesting that factors such as IGF2R and IRA, not well
described before, could interact with IGF2, potentially
modulating the role of IGF2 in adrenocortical tumorigen-
esis. Mean levels of IGF1 and IGFBP6 were signiﬁcantly
lower in ACCs as compared with NAs. Additionally, this
study demonstrates that treatment of human ACC cells with
OSI-906, a dual IGF1R/IR inhibitor, reduces cell pro-
liferation and that combined treatment with linsitinib and
mTOR inhibitors can have additive antiproliferative effects.
A high mRNA and protein expression of IGF2 is found
in most evaluated samples, in agreement with the already
well-known IGF2 overexpression in 70-90% of ACCs [8–
17]. IGF1R protein expression was demonstrated in all the
evaluated ACC samples and an intermediate-to-high stain-
ing was observed in more than 50% of cases. These data are
in agreement with previous studies describing IGF1R
expression in most ACCs [11, 14, 38]. The protein
expression of IR in most ACCs has been previously
described as well [38], however, to the best of our knowl-
edge, the differential expression of IRA and IRB isoforms
of the IR in ACCs, has never been explored. Unfortunately,
to the best of our knowledge, there are currently no anti-
bodies available to distinguish between the IR isoforms. We
could therefore only evaluate IR isoform expression at
mRNA level. While IRB is considered as the main mediator
of metabolic effects of insulin and IGFs in adult tissue, IRA
is an isoform of the IR, predominantly expressed during
fetal development and is considered as an important med-
iator of growth-promoting effects of insulin and IGFs [19].
IRA has a higher afﬁnity for IGF2 compared with the
IGF1R and its expression in malignant tumor tissue has
Fig. 4 Effect of linsitinib (OSI-906 indicated as Osi), alone or in
combination with the mTOR inhibitors sirolimus (S) or everolimus
(E), on H295R a–d and HAC15 e–h cell proliferation. Results are
expressed as DNA content/well. Two different conditions have been
tested: medium with high a, c, e, g or low serum b, d, f, h. The data are
expressed as the percentage of control and represent the mean ± SEM.
Control is set as 100%. *p < 0.05; **p < 0.01; ***p < 0.001; xp < 0.05
vs. control; xxp < 0.01 vs. control; xxxp < 0.001 vs. control
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been suggested to be involved in cancer development [19].
To our knowledge this is the ﬁrst study demonstrating the
presence of IRA in ACCs and showing that in these cancers,
IRA is often expressed at higher level compared with
IGF1R and IRB. The expression of IGF2 and the IGF1R
has suggested a potential role of an IGF2-IGF1R autocrine
loop in adrenocortical tumorigenesis [39]. The current study
suggests a role of IRA as potential additional mediator of
the IGF2 effects in ACC. However, in addition to the tyr-
osine kinase receptors involved in the IGF pathway, also
IGF2R and IGFBPs could play a role in modulating the
IGFs effects. The IGF2R serves a function in the degrada-
tion of IGF2, intracellular trafﬁcking of lysosomal enzymes
and activation of transforming growth factor beta. Down-
regulation of IGF2R has been found in some type of cancers
and it has been suggested that IGF2R could play a role as a
tumor suppressor gene in some malignancies [40, 41]. Loss
of heterozygosis at the locus of IGF2R gene has been
reported to be a frequent event in ACC, supporting a
potential role of IGF2R as a tumor suppressor gene also in
ACC development [42]. However, a low protein expression
of IGF2R in ACC has never been described. Conversely,
the current study demonstrates the presence of a high
IGF2R protein expression in most ACCs, suggesting that a
high level of IGF2R protein might counteract the growth-
stimulating effects of IGF2 in adrenocortical tumorigenesis.
In line with previously published data, in the current study a
variable expression of IGFBPs was found in ACCs [10, 43].
Fig. 5 a, b: Effect of linsitinib (OSI-906 indicated as Osi), alone or in
combination with the mTOR inhibitors sirolimus [(S); a] or everolimus
[(E); b], on Annexin V as a measure of induction of apoptosis in
H295R cell line. The data are expressed as the percentage of control
and represent the mean ± SEM. Control is set as 100%. *p < 0.05 vs.
Osi alone; xxxp < 0.001 vs. control. c, d Effect of linsitinib (Osi), alone
or in combination with the mTOR inhibitors sirolimus c or everolimus
d, on cell cycle in H295R cell line. The data are expressed as mean ±
SEM. *p < 0.05 and **p < 0.01 vs. S c or E d alone; xp < 0.05 and xxp
< 0.01 vs. control
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Several correlations between the mRNA expression of dif-
ferent components of the IGF pathway were found sug-
gesting the existence of common mechanisms of regulation.
However no correlations with clinical-pathological para-
meters were found. This lack of correlation might be related
to the small sample size and to the complexity of the IGF
pathway. Among the IGFBPs evaluated, the IGFBP
expressed at higher levels was IGFBP2, whereas IGFBP6
was expressed at lowest level. Additionally the expression
of IGFBP6 was signiﬁcantly lower in ACCs than in NAs.
Therefore, whether high IGFBP2 and/or low IGFBP6 could
play a role in the regulation of IGF pathway in adrenocor-
tical tumorigenesis deserves further investigation. Addi-
tionally the IGFBP expressed at highest levels within ACC
was IGFBP2, which has been recently suggested as a
potential target for treatment in some type of cancers [44].
Therefore, in future studies it might be interesting to better
explore the role of this and other IGFBPs as potential target
for treatment in ACC as well.
The IGF pathway has been considered as one of the most
promising targets for a novel medical treatment modality in
patients with ACC [11, 14, 26, 45]. In preclinical models of
ACC, two types of drugs targeting the IGF1R, i.e., NVP-
AEW541, a selective IGF1R kinase inhibitor and IMC-12,
an IGF1R antibody, have been reported to have anti-
proliferative effects [11, 14], thus encouraging the devel-
opment of clinical trials in ACC patients using drugs
targeting the IGF pathway. The current study conﬁrms that
linsitinib (OSI-906), an IGF1R/IR inhibitor, inhibits the
proliferation of the human ACC cell lines H295R and
HAC15 in vitro already at a concentration lower than the
concentrations reached in vivo in humans (about 5 × 10−6
M). However linsitinib has been recently tested in ACC
patients in a phase III clinical trial (NCT00924989). The
results of this study have been recently published [46]
showing that only a very small subgroup of patients seems
to beneﬁt from treatment with this drug, and improvements
in overall or progression-free survival were not observed.
These apparent controversial results between preclinical and
clinical studies, could be explained by several reasons. First,
it might indicate that our preclinical models are not enough
representative for the population of patients with ACC,
because these tumors are heterogeneous. The role of the
IGF pathway as a potential target for treatment in ACC
might have been overestimated, as suggested by the fact that
up-to-date in vivo experiments demonstrated that isolated
IGF2 overexpression has no oncogenic potential [47]. Since
disappointing results emerged in clinical trials adopting
different types of drugs targeting the IGF pathway in dif-
ferent types of malignancies, despite apparently promising
preclinical data [48], it could be hypothesized that current
strategies adopted to target this pathway might still be
inadequate. Indeed, biomarkers that can predict tumor
response to IGF-targeting drugs, that might drive the
selection of patient candidates to these drugs, have not been
identiﬁed yet. Additionally, the complexity of the system
could have been underestimated (such as the expression of
potential regulators of the IGF pathway, as IGF2R in ACC)
and the existence of interfering factors may not have been
characterized yet. For example, in case of ACC patients the
potential pharmacokinetic interactions between mitotane
and drugs acting on the IGF pathway should be better
investigated. Mitotane is a strong inducer of CYP3A4 and
was shown to decrease bioavailability of sunitinib in
patients with ACC [49]. Finally, targeting only the IGF
pathway might not be sufﬁcient to suppress cell growth
because other pathways, that in part also interact with the
IGF pathway (e.g. the mTOR pathway) are still activated.
As such, before to ﬁnally declare a “game over” [47] for the
role of IGF2 in adrenocortical tumorigenesis and as
potential target for novel treatment in ACC patients, it could
be probably useful to return to the bench and try to better
explore the IGF pathway in its whole complexity. In line
with this, the results of the current study point out that ACC
express components of the IGF pathway, such as IRA and
IGF2R, that have not been considered before.
In a previous study from our group, it was demonstrated
that mTOR inhibitors inhibit cell proliferation in H295R and
SW13 human ACC cell lines, but in H295R, probably as
consequence of the IGF2 overexpression, this treatment could
activate two potential pathways of escape to treatment with
traditional mTOR inhibitors, i.e. the AKT and ERK pathways
[25]. These data provide the rational for experiments com-
bining mTOR inhibitors and drugs targeting the IGF pathway
in ACC. In the current study the effects of linsitinib in
combination with mTOR inhibitors were evaluated and the
results of these experiments demonstrated that these com-
pounds can have additive antiproliferative effects in some of
the tested conditions. Particularly, additive antiproliferative
effects were more pronounced when the experiments were
performed using medium with low serum, suggesting that cell
environment and the presence of growth factors different from
IGF2 could inﬂuence the effects of these combination of
compounds. These results are in line with a recently published
phase I study demonstrating that a subgroup (about 40%) of
ACC patients treated with cixutumumab (IGF1R inhibitor)
and temsirolimus experienced a long term disease stabiliza-
tion [28]. These results suggest that treatment strategies
combining mTOR inhibitors and linsitinib warrant further
investigation, although considering the heterogeneous
expression of the main components of the IGF pathway in the
different ACC samples, the apparently modest anti-
proliferative effects observed at a low concentration of these
compounds as well as the potential limits of the used human
cell lines as model of human ACC, caution is recommended
before to move from the bench to the bedside.
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A potential limitation of the current study is the small
sample size. Although the number of samples included is
reasonable considering the rarity of ACC, the reported
results require conﬁrmation in larger series of samples.
In conclusion, the present study describes the IGF
pathway in ACC and explores the response to the combined
treatment with the dual IGF1-/IR inhibitor linsitinib, and
mTOR inhibitors in in-vitro models of ACC, demonstrating
that human ACC express IGF2R and IRA which, in addi-
tion to IGF2 and its receptor IGF1R, might modulate the
IGFs effects and linsitinib and mTOR inhibitors have
additive antiproliferative effects.
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